美国部分性葡萄胎短串联重复基因分型检测可及性有限
部分性葡萄胎的致病性定义为二雄三倍体妊娠,需短串联重复(STR)基因分型对福尔马林固定流产标本确诊。调查发现美国仅13家实验室提供该检测,其中4家不接收外部标本,商业实验室16家中仅1家提供,故提出反映诊断确定性水平的新报告命名系统。
要点
- 部分性葡萄胎确诊需STR基因分型,但美国可及性有限。
- 调查中仅13家实验室提供检测,商业实验室16家中仅1家提供。
- 建议采用反映诊断确定性水平的新报告命名系统。
核心结论
- 美国对福尔马林固定流产标本进行STR基因分型检测的可及性有限,难以满足部分性葡萄胎精准诊断需求。
研究设计与样本
- 调查美国分子病理学会会员并直接查询选定的美国商业实验室。
主要发现
- 共确定13家实验室提供福尔马林固定流产标本的STR基因分型检测,其中11家位于学术中心、2家位于非学术中心、0家为商业实验室。
- 13家中有4家不接收其医疗系统外病理医生提交的标本。
- 在接收外部标本的9家中,8家要求标本先在其外科病理科进行正式诊断会诊。
- 未提供该检测的实验室受访者报告的首要原因是需求不足。
- 直接查询客户服务代表显示,美国16家选定商业参考实验室中仅1家提供该检测。
关键数值与推荐
- 部分性葡萄胎的致病性定义为二雄三倍体妊娠,需STR基因分型对福尔马林固定流产标本确诊。
- 作者提出新的报告命名系统,根据诊断基于基因型分析、倍性分析或仅形态学来反映部分性葡萄胎的诊断确定性水平。
临床怎么用
- 病理医生应了解STR基因分型检测的可及性限制,并在可获得时优先选择基因型分析而非倍性分析评估部分性葡萄胎。
- 可采用反映诊断确定性水平的报告命名系统来沟通部分性葡萄胎诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pathogenetic definition of a partial hydatidiform mole (PHM) is a diandric triploid gestation, thereby requiring short tandem repeat (STR) genotype testing for definitive diagnosis in formalin-fixed products of conception (POC) specimens. However, recent literature shows there is limited access to this test, even in high-income countries. Therefore, we hypothesized that in the United States, access to this test would be enriched in academic centers and commercial reference laboratories. We surveyed the Association for Molecular Pathology membership and directly queried selected commercial laboratories in the United States. The survey identified 13 laboratories (11 in academic centers, 2 in nonacademic centers, 0 commercial laboratories) that offered STR genotype testing for molar pregnancy diagnosis in formalin-fixed POC specimens. Four of the 13 laboratories did not accept specimens from pathologists outside of their health care system. Among the 9 who did, 8 first required that the specimen undergo formal diagnostic consultation in their surgical pathology department. Insufficient demand was the leading rationale reported by survey respondents from laboratories that did not offer this test at all. Separately, direct queries with client service representatives showed that only 1 of 16 selected commercial reference laboratories in the United States offered this test. Given the limited access to STR genotype testing, we propose a new reporting nomenclature system that reflects the level of diagnostic certainty for PHM, depending on whether the diagnosis is based on genotype analysis, ploidy analysis, or morphology alone. Further efforts are needed to educate pathologists who do have access to genotype analysis to select that test format rather than ploidy analysis to evaluate the concern for PHM.
引用
- Warren L, Tafe LJ, Devine WP, et al. Limited Availability of Short Tandem Repeat Genotype Testing in the United States for Diagnosis of Partial Hydatidiform Mole: A Dilemma for Practicing Precision Medicine. Am J Surg Pathol. 2026. PMID: 42424170. doi:10.1097/PAS.0000000000002558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。